Gastroenterology News

New survey results from the AMA illustrate the burden of prior authorization, with many physicians reporting that it leads to serious patient harms, delays care, reduces work productivity and more.

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%.

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.

Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted that the first step in building an LGBTQ-friendly gastroenterology practice starts with “just normalizing it.”

The LGBTQIA+ community has long-endured decades of stigma and discrimination.

According to a 2021 Gallup poll, 7.1% of the U.S. population reported identifying as LGBTQIA+ — “nearly double” the percentage in 2012 — including one in five Generation Z adults.

As we enter the second half of 2024, it is important to understand some tax law changes that became effective this year and could affect your retirement savings and tax planning.

The AMA House of Delegates adopted several new policies to promote public health at its annual meeting.